We Offer Worldwide Shipping
Login Wishlist

Nicorandil

$64

  • Brand : BIOFRON

  • Catalogue Number : BN-O1032

  • Specification : 98%(HPLC)

  • CAS number : 65141-46-0

  • Formula : C8H9N3O4

  • Molecular Weight : 211.17

  • PUBCHEM ID : 47528

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O1032

Analysis Method

Specification

98%(HPLC)

Storage

-20℃

Molecular Weight

211.17

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]

Synonyms

3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]-/Nitorubin/Perisalol/2-(pyridine-3-carbonylamino)ethyl nitrate/2-[(Pyridin-3-ylcarbonyl)amino]ethylnitrat//NicorandilIkorel/SG-75/Dancor/Nikoran/Nicorandilum/2-[(Pyridin-3-ylcarbonyl)amino]ethyl nitrate/N-(2-hydroxyethyl)nicotinamide nitrate ester/2-[(3-Pyridinylcarbonyl)amino]ethyl nitrate/Adancor/N-[2-(nitroxy)ethyl]-3-pyridine carboxamide/Sigmart/2-Nicotinamidoethyl nitrate

IUPAC Name

Density

1.3±0.1 g/cm3

Solubility

Flash Point

230.0±23.2 °C

Boiling Point

456.7±25.0 °C at 760 mmHg

Melting Point

92ºC

InChl

InChI=1S/C28H39ClO7/c1-15-13-21(36-22(32)16(15)2)25(5,33)28(35)12-11-27(34)18-14-20(31)26(29)9-6-7-19(30)24(26,4)17(18)8-10-23(27,28)3/h6-7,17-18,20-21,31,33-35H,8-14H2,1-5H3/t17-,18+,20+,21+,23-,24-,25-,26-,27+,28-/m0/s1

InChl Key

LBHIOVVIQHSOQN-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:65141-46-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

24838374

Abstract

The stable coronary artery disease (SCAD) population is a heterogeneous group of patients both for clinical presentations and for different underlying mechanisms. The recent European Society of Cardiology guidelines extensively review SCAD from its definition to patients’ diagnostic and therapeutic management. In this review, we deal with five topics that, in our opinion, represent the most intriguing, novel and/or clinically relevant aspects of this complex coronary condition. Firstly, we deal with a peculiar SCAD population: patients with angina and ‘normal’ coronary arteries. Secondly, we reinforce the clinical importance of a diagnostic approach based on the pretest probability of disease. Thirdly, we review and critically discuss the novel pharmacological therapies for SCAD patients. Finally, we analyse the results of the most recent clinical trials comparing revascularization versus optimal medical therapy in SCAD patients and review the currently recommended use of intracoronary functional evaluation of stenosis.

Title

Stable Angina Pectoris

Author

Marco Valgimigli 1, Simone Biscaglia

Publish date

Jul-14

PMID

29728754

KEYWORDS

ATP-sensitive K+ channels; Cerebral artery; Nicorandil; Nitric oxide.

Title

The Unique Action of Nicorandil on Cerebral Circulation

Author

Hiroyuki Kinoshita 1 2, Shinji Kawahito 3, Kazumi Takaishi 4

Publish date

Jun-18

PMID

27784845

Abstract

Potassium channels and transporters maintain potassium homeostasis and play significant roles in several different biological actions via potassium ion regulation. In previous decades, the key revelations that potassium channels and transporters are involved in the production of gastric acid and the regulation of secretion in the stomach have been recognized. Drugs used to treat peptic ulceration are often potassium transporter inhibitors. It has also been reported that potassium channels are involved in ulcerative colitis. Direct toxicity to the intestines from nonsteroidal anti-inflammatory drugs has been associated with altered potassium channel activities. Several reports have indicated that the long-term use of the antianginal drug Nicorandil, an adenosine triphosphate-sensitive potassium channel opener, increases the chances of ulceration and perforation from the oral to anal regions throughout the gastrointestinal (GI) tract. Several of these drug features provide further insights into the role of potassium channels in the occurrence of ulceration in the GI tract. The purpose of this review is to investigate whether potassium channelopathies are involved in the mechanisms responsible for ulceration that occurs throughout the GI tract.

KEYWORDS

Gastrointestinal tract; H⁺/K⁺-ATPase; Potassium channels; Ulceration.

Title

Potassium Channelopathies and Gastrointestinal Ulceration

Author

Jaeyong Han 1, Seung Hun Lee 2, Gerhard Giebisch 1, Tong Wang 1

Publish date

2016 Nov 15


Description :

Empty ...